Alnylam Pharmaceuticals, Inc.
ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
Last updated:
Abstract:
The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
Status:
Application
Type:
Utility
Filling date:
13 Feb 2019
Issue date:
3 Oct 2019